You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The story of COVID-19 now seems so familiar: from the first reported case of a new respiratory infection in China in December 2019, to a pandemic that rapidly changed the world. Respiratory clinicians and scientists were at the forefront of delivering healthcare for people with COVID-19, leading efforts to understand this novel virus and disease, and developing and testing strategies to better prevent and treat it. These endeavours extended not only to the acute illness, but also to understanding the longer-term consequences. The pace of knowledge acquisition was rapid but is now maturing. This Monograph therefore provides a timely and valuable state-of-the-art summary for clinicians and scientists on our understanding of this virus and its consequences to date. It is essential reading for all those involved in the care of people who are or who have been affected by COVID-19.
Complex breathlessness (breathlessness with an unclear cause or that appears disproportionate to underlying causes) is an important and often neglected condition that presents a challenge to both patients and clinicians. This Monograph aims to provide clinicians at all levels with a comprehensive guide to complex breathlessness. Covering all aspects of this challenging clinical scenario, it will prove a useful resource when faced with a symptomatic breathless patient with no obvious underlying cause or with disproportionate symptoms. Several less commonly considered clinical entities and their associated features are highlighted, and approaches to breathlessness management are suggested in the absence of a clear diagnosis or set of abnormalities on investigation.
This Monograph provides the general respiratory physician with a working reference based on the latest literature and expert opinion. The initial chapter provides a contemporaneous global perspective of the epidemiology of occupational and environmental lung diseases in an ever-evolving landscape. The book then goes on to consider specific occupational lung diseases. Each chapters has a clear clinical focus and considers: key questions to ask in the history; appropriate investigations to undertake; differential diagnoses; and management. Controversies or diagnostic conundrums encountered in the clinic are also considered, and further chapters are more broadly centred on the non-workplace environment; specifically, the respiratory symptoms and diseases associated with both the outdoor and indoor environments.
In May 2023, WHO declared that COVID-19 was no longer a public health emergency of international concern. In 2024, COVID-19 certainly has not gone away, but we can now take a more reflective look at the pandemic. This issue of the ERS Monograph does just that, bringing together a truly international group of experts, as befits a global illness, to consider areas such as: long-term sequelae in airway disease, interstitial lung disease, and in the immunocompromised; therapeutics in the community, in hospital and in the intensive care unit; and the pathophysiology and management of long COVID. The Guest Editors also consider the impact of COVID-19 on clinical research and scientific publishing, as well as looking to the future, considering what can be learnt from the pandemic.
Severe asthma is a form of asthma that responds poorly to currently available medication, and its patients represent those with greatest unmet needs. In the last 10 years, substantial progress has been made in terms of understanding some of the mechanisms that drive severe asthma; there have also been concomitant advances in the recognition of specific molecular phenotypes. This ERS Monograph covers all aspects of severe asthma – epidemiology, diagnosis, mechanisms, treatment and management – but has a particular focus on recent understanding of mechanistic heterogeneity based on an analytic approach using various ‘omics platforms applied to clinically well-defined asthma cohorts. How these advances have led to improved management targets is also emphasised. This book brings together the clinical and scientific expertise of those from around the world who are collaborating to solve the problem of severe asthma.
Diagnosing rare diseases can be challenging, and treating these conditions is complex because of their often quite specific needs and treatment options. To address this, the European Respiratory Society (ERS) has published Rare Diseases of the Respiratory System. Structured into thematic sections, the book covers: the identification of rare diseases of the respiratory system and their differential diagnosis; rare diseases of the lung interstitium; rare diseases of the airways or alveoli; and rare pulmonary vascular diseases. The Guest Editors and authors belong to and/or support the vision and mission of the European Reference Network for Rare Diseases of the Respiratory System (ERN-LUNG), which offers expert support to both patients and professionals. As such, this comprehensive book will prove an excellent resource for healthcare professionals, researchers and students interested in rare diseases of the respiratory system.
This Monograph offers a comprehensive and up-to-date overview of AATD. It covers basic biology, genetics, laboratory diagnostics and the major organ manifestations; describes the clinical presentation of AATD in both adults and children; and features chapters on genetic counselling, patient views and future therapies. The content has been tailored to meet the needs of the physician, who takes care of lung and liver patients in daily practice, and the general practitioner, who is responsible for the medical guidance of these patients.
A great deal of knowledge about eosinophilic lung diseases has been gained in the last few years, but unanswered questions concerning eosinophil biology still remain. It is in this context that this Monograph was developed. Broad in scope, the book bases its approach to the management of eosinophilic lung diseases on a fundamental understanding of eosinophil biology in health and disease. State-of-the-art reviews written by world-leading authorities and up-and-coming stars in the field take the reader on a journey through the different eosinophilic lung diseases. This Monograph will ensure the practicing clinician is better equipped to recognise and treat patients with eosinophilia, as well as appreciate the advances coming in the near future.
COPD remains a major cause of ill health, disability, healthcare costs and premature mortality. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results. This Monograph provides an up-to-date overview of what is happening in this exciting field, both at a basic and a clinical level. Beginning, crucially, with the patient’s perspective, the chapters that follow consider the best way to define COPD, changes in the disease’s incidence and prevalence, and offer new insights into the role of the microbiome in COPD, advances in imaging and treatment options, both pharmacological and non-pharmacological. Taken together, these chapters are an important contribution to the Monograph series and the COPD field in general.
This Monograph provides a comprehensive overview of tobacco cessation, from health policy to patient care. Broad in scope, this state-of-the art collection is broken down into four sections: the changing landscape of the tobacco epidemic and challenges to curb it; treatment of tobacco dependence (pharmacotherapy, behavioural support); improving the care of patients with particular conditions who smoke (asthma, COPD, TB, cardiovascular diseases, etc.); and prevention. It also deals with some of the more controversial topics such as e-cigarettes and web applications. Readers will gain an understanding of how to implement smoking cessation into their everyday practice, but will also expand their knowledge about the policy and systems changes needed for population-wide smoking cessation.